3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Glioma
3
Glioblastoma
3
Astrocytoma
2
Whooping Cough
1
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumococcal Infections
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Measles
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Hepatitis B
1
HIV Infections
1
Gliosarcoma
1
Carcinoma
1
Advanced Cancer
1
Interventions
Imatinib Mesylate
86
nilotinib
59
fludarabine phosphate
46
Cyclophosphamide
45
Mycophenolic Acid
37
Whole-Body Irradiation
35
Dasatinib
32
fludarabine
31
Tacrolimus
29
Cyclosporine
24
Busulfan
23
Peripheral Blood Stem Cell Transplantation
22
Methotrexate
20
bosutinib
18
Cytarabine
18
Granulocyte Colony-Stimulating Factor
16
Filgrastim
16
Melphalan
14
thymoglobulin
13
Antilymphocyte Serum
13
Stem Cell Transplantation
12
sargramostim
11
Thiotepa
11
Interferon-alpha
10
Cord Blood Stem Cell Transplantation
9
asciminib
8
Cyclosporins
8
ponatinib
7
Sirolimus
7
Radiotherapy
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Tetanus Toxoid
×
Clear all
NCT01611298
2020-04-21
TAR
Baylor College of Medicine
Phase NA
Completed
7 enrolled
8 charts